Fig. 3

Percentage of patients who reached sitting systolic blood pressure (siSBP) and low-density lipoprotein cholesterol (LDL-C) goals after fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV) treatment, fimasartan 120 mg alone (FMS) treatment, or rosuvastatin 20 mg alone (RSV) treatment at week 8